Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?
Assaf Berger(Neurological Surgery), Douglas Kondziolka(Neurological Surgery), John G. Golfinos(NYU Langone Health), Monica Mureb(Westchester Medical Center), Amy Palermo(NYU Langone Health), Jeffrey S. Weber(NYU Langone Health), Kathleen Madden(NYU Langone Health), Janice M. Mehnert(New York University), Erik P. Sulman(NYU Langone Health), Anna C. Pavlick(Cornell University), Kenneth Bernstein(NYU Langone Health), Joshua S. Silverman(NYU Langone Health), Jason Gurewitz(New York University), Juan Diego Alzate(Neurological Surgery), Bernadine R. Donahue(Maimonides Medical Center), Reed Mullen(Neurological Surgery)
Cited by 13
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k